Zydus Pharmaceuticals announces approval for ANDA 218349, reflecting the company's continued strategy of leveraging generic drug pipeline expansion to diversify its market revenue streams. The regulatory clearance provides Zydus with an immediate commercial opportunity to capture a segment of the U.S. market for this therapeutic category.